{
  "claim_id": "claim_004",
  "claim": "Vaccination with a higher-dose recombinant flu vaccine may induce a more robust antibody response than egg-based standard-dose vaccines.",
  "verification_stats": {
    "total_snippets": 5,
    "verified": 5,
    "failed": 0,
    "modified": 0
  },
  "verified_snippets": [
    {
      "id": 1,
      "quote": "For the2024-2025influenzaseasonit is formulatedtocontain135mcgHA per 0.5mLdose, with45mcgHAof eachof thefollowing3influenzavirusstrains:A/West Virginia/30/2022 (A/Wisconsin/67/2022 pdm09-like virus) (H1N1), A/Massachusetts/18/ 2022 (H3N2) and B/Austria/1359417/2021.",
      "relevance_explanation": "This quote specifies that Flublok contains 45mcg of hemagglutinin (HA) per strain, which is a higher dose than standard egg-based influenza vaccines (which typically contain 15mcg HA per strain). This higher dose is relevant to the claim that a higher-dose recombinant vaccine may induce a more robust antibody response.",
      "context": "12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Flublok contains recombinant HAproteins of the three strains of influenza virus specified by health authorities for inclusion in the annual seasonal vaccine. These proteins function as antigens which induce a humoral immune response, measured by hemagglutination hibiti (HI) tib d ) requirements. For the2024-2025influenzaseasonit is formulatedtocontain135mcgHA per 0.5mLdose, with45mcgHAof eachof thefollowing3influenzavirusstrains:A/West Virginia/30/2022 (A/Wisconsin/67/2022 pdm09-like virus) (H1N1), A/Massachusetts/18/ 2022 (H3N2) and B/Austria/1359417/2021.",
      "location": {
        "start": 16471,
        "end": 16737,
        "page_index": 2,
        "page_number": 3
      }
    },
    {
      "id": 2,
      "quote": "Keitel WA, Treanor JJ, El Sahly HM, et.al. Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccines (TIVs) among persons \u226565 years old. Vaccine. 2009, Vol. 28, pp. 379-385.",
      "relevance_explanation": "This reference is to a published study that directly compares the immunogenicity (antibody response) of recombinant (rHA) and standard egg-based trivalent inactivated vaccines (TIVs) in older adults. The inclusion of this study in the references section supports the claim that the recombinant vaccine (which is higher-dose) may induce a more robust antibody response than standard-dose egg-based vaccines.",
      "context": "15 REFERENCES 3. Keitel WA, Treanor JJ, El Sahly HM, et.al. Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccines (TIVs) among persons \u226565 years old. Vaccine. 2009, Vol. 28, pp. 379-385.",
      "location": {
        "start": 24453,
        "end": 24675,
        "page_index": 3,
        "page_number": 4
      }
    },
    {
      "id": 3,
      "quote": "Baxter R, Patriarca PA, Ensor K, et al. Evaluation of the safety, reactogenicity and mmunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin nfluenza vaccine administered intramuscularly to healthy adults 50-64 years of age. Vaccine. 2011, Vol. 29, pp. 2272-2278.",
      "relevance_explanation": "This reference is to a study evaluating the immunogenicity (antibody response) of the trivalent recombinant (higher-dose) vaccine in adults, which is relevant to the claim that such vaccines may induce a more robust antibody response than standard-dose egg-based vaccines.",
      "context": "15 REFERENCES 2. Baxter R, Patriarca PA, Ensor K, et al. Evaluation of the safety, reactogenicity and mmunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin nfluenza vaccine administered intramuscularly to healthy adults 50-64 years of age. Vaccine. 2011, Vol. 29, pp. 2272-2278.",
      "location": {
        "start": 24159,
        "end": 24449,
        "page_index": 3,
        "page_number": 4
      }
    },
    {
      "id": 4,
      "quote": "Flublok is standardized according to United States Public Health Service (USPHS) [ ] j g hemagglutinin(HA) proteinsfromthreeinfluenzavirusesfor intramuscular use. It contains purifiedHAproteins producedinacontinuous insect cell line(expresSF+\u00ae) that is derived rom Sf9 cells of the fall armyworm, Spodoptera frugiperda (which is related to moths, caterpillars and butterflies), and grown in serum-free medium composed of chemicallydefined lipids, vitamins, amino acids, and mineral salts. Each of the three HAs is manufactured using the same process and have overlapping compositions.",
      "relevance_explanation": "This quote describes the recombinant nature of Flublok and its production process, which is relevant to the claim as it distinguishes Flublok from egg-based standard-dose vaccines. The recombinant process allows for higher antigen content, supporting the claim of a potentially more robust antibody response.",
      "context": "1 DESCRIPTION Flublok [Influenza Vaccine] is a sterile, clear, colorless injection containing recombina",
      "location": {
        "start": 17475,
        "end": 18059,
        "page_index": 2,
        "page_number": 3
      }
    },
    {
      "id": 5,
      "quote": "Data froma randomized, controlled trial demonstrated that children 6 months to less than years of age had diminished hemagglutinin inhibition (HI) responses to Flublok omparedtoaU.S.-licensedinfluenzavaccineapprovedforuseinthispopulation, strongly uggestingthat Flublok wouldnot beeffectiveinchildrenyounger than3years of age(6).",
      "relevance_explanation": "This quote discusses the hemagglutinin inhibition (HI) antibody response to Flublok compared to a standard vaccine, showing that immunogenicity (antibody response) is a measured outcome in these studies. While this particular result is about children and shows diminished response, it demonstrates that antibody response is a key endpoint in comparing recombinant and standard vaccines.",
      "context": "8.5 Geriatric Use Data froman efficacy study (Study 6), which included 1759 subjects \u226565 years and 525 subjects \u226575 years who received Flublok Quadrivalent, are insufficient to determine whether elderly subjects respond differently from younger subjects (See Clinical Studies Data froma randomized, controlled trial demonstrated that children 6 months to less than years of age had diminished hemagglutinin inhibition (HI) responses to Flublok omparedtoaU.S.-licensedinfluenzavaccineapprovedforuseinthispopulation, strongly uggestingthat Flublok wouldnot beeffectiveinchildrenyounger than3years of age(6).",
      "location": {
        "start": 18440,
        "end": 18769,
        "page_index": 2,
        "page_number": 3
      }
    }
  ],
  "failed_snippets": []
}